154 related articles for article (PubMed ID: 23368976)
1. Retigabine as add-on treatment of refractory epilepsy--a cost-utility study in a Swedish setting.
Kristian B; Wachtmeister K; Stefan F; Forsgren L
Acta Neurol Scand; 2013 Jun; 127(6):419-26. PubMed ID: 23368976
[TBL] [Abstract][Full Text] [Related]
2. Lacosamide as treatment of epileptic seizures - cost utility results for Sweden.
Bolin K; Berggren F; Forsgren L
Acta Neurol Scand; 2010 Jun; 121(6):406-12. PubMed ID: 20199516
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of add-on therapy with pregabalin in patients with refractory partial epilepsy.
Vera-Llonch M; Brandenburg NA; Oster G
Epilepsia; 2008 Mar; 49(3):431-7. PubMed ID: 17822431
[TBL] [Abstract][Full Text] [Related]
4. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisal.
Craig D; Rice S; Paton F; Fox D; Woolacott N
Pharmacoeconomics; 2013 Feb; 31(2):101-10. PubMed ID: 23341194
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of lacosamide in the adjunctive treatment of patients with refractory focal epilepsy in Belgium.
Simoens S; De Naeyer L; Dedeken P
CNS Drugs; 2012 Apr; 26(4):337-50. PubMed ID: 22452528
[TBL] [Abstract][Full Text] [Related]
6. Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system.
Geitona M; Stamuli E; Giannakodimos S; Kimiskidis VK; Kountouris V; Charokopou M; Christou P
J Med Econ; 2019 Apr; 22(4):359-364. PubMed ID: 30652931
[TBL] [Abstract][Full Text] [Related]
7. Lacosamide as adjunctive therapy for partial-onset epileptic seizures: a review of the clinical and economic literature.
Simoens S
Curr Med Res Opin; 2011 Jul; 27(7):1329-38. PubMed ID: 21561394
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
Tompson DJ; Crean CS; Reeve R; Berry NS
Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
[TBL] [Abstract][Full Text] [Related]
10. Retigabine for partial onset seizures.
Rheims S; Ryvlin P
Expert Rev Neurother; 2012 May; 12(5):509-17. PubMed ID: 22550979
[TBL] [Abstract][Full Text] [Related]
11. Retigabine: fewer drug interactions.
Prescrire Int; 2012 Mar; 21(125):61. PubMed ID: 22428181
[TBL] [Abstract][Full Text] [Related]
12. Lacosamide: an adjunctive agent for partial-onset seizures and potential therapy for neuropathic pain.
Harris JA; Murphy JA
Ann Pharmacother; 2009 Nov; 43(11):1809-17. PubMed ID: 19843834
[TBL] [Abstract][Full Text] [Related]
13. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
Splinter MY
Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
[TBL] [Abstract][Full Text] [Related]
14. Real life pharmaceutical treatment patterns for adult patients with focal epilepsy in Germany: a longitudinal and cross-sectional analysis of recently approved anti-epileptic drugs.
Groth A; Wilke T; Borghs S; Gille P; Joeres L
Ger Med Sci; 2017; 15():Doc09. PubMed ID: 28638313
[No Abstract] [Full Text] [Related]
15. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate.
Patsalos PN; Berry DJ
Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of epilepsy surgery in a cohort of patients with medically intractable partial epilepsy--preliminary results].
Picot MC; Neveu D; Kahane P; Crespel A; Gélisse P; Hirsch E; Derambure P; Dupont S; Landré E; Chassoux F; Valton L; Vignal JP; Marchal C; Rougier A; Lamy C; Semah F; Biraben A; Arzimanoglou A; Petit J; Thomas P; Dujols P; Ryvlin P
Rev Neurol (Paris); 2004 Jun; 160 Spec No 1():5S354-67. PubMed ID: 15331984
[TBL] [Abstract][Full Text] [Related]
17. Retigabine as adjunctive therapy in adults with partial-onset seizures: integrated analysis of three pivotal controlled trials.
Porter RJ; Burdette DE; Gil-Nagel A; Hall ST; White R; Shaikh S; DeRossett SE
Epilepsy Res; 2012 Aug; 101(1-2):103-12. PubMed ID: 22512894
[TBL] [Abstract][Full Text] [Related]
18. Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis.
Luszczki JJ; Zagaja M; Miziak B; Kondrat-Wrobel MW; Zaluska K; Wroblewska-Luczka P; Adamczuk P; Czuczwar SJ; Florek-Luszczki M
Pharmacology; 2018; 101(1-2):22-28. PubMed ID: 28926841
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
[TBL] [Abstract][Full Text] [Related]
20. Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.
Jentink J; Boersma C; de Jong-van den Berg LT; Postma MJ
J Med Econ; 2012; 15(5):862-8. PubMed ID: 22494266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
